| Stage | PLAB | % of rev | NVDA | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $216M | 100.00% | $96.2B | 100.00% | NVDA ×445.37 |
| Gross profit | $72M | 33.20% | $72.1B | 74.98% | NVDA +41.8pp |
| Operating income | $46M | 21.06% | $63.7B | 66.24% | NVDA +45.2pp |
| Pre-tax income | $55M | 25.40% | $71.5B | 74.32% | NVDA +48.9pp |
| Net income | $44M | 20.31% | $59.7B | 62.03% | NVDA +41.7pp |
| Stage | PLAB | NVDA | Gap · A − B |
|---|---|---|---|
| Revenue | $216M100.00% | $96.2B100.00% | NVDA ×445.37 |
| Gross profit | 33.20%$72M | 74.98%$72.1B | NVDA +41.8pp |
| Operating income | 21.06%$46M | 66.24%$63.7B | NVDA +45.2pp |
| Pre-tax income | 25.40%$55M | 74.32%$71.5B | NVDA +48.9pp |
| Net income |
| 20.31%$44M |
| 62.03%$59.7B |
| NVDA +41.7pp |
None
No disclosed counterparties: PLAB.